Kidney Cancer Precision Diagnosis
At Fosun Health, kidney cancer diagnosis is not just about “finding a mass”—it is about determining the tumor’s exact location, size, and relationship to the kidney, as well as its molecular type, to design a plan that preserves your kidney function and protects you from long-term dialysis. Our streamlined pathway delivers answers within days:
- Contrast-Enhanced CT (CT Urography): The gold standard for kidney cancer diagnosis. Reveals tumor size, location, enhancement pattern (clear cell vs. papillary), invasion into veins, and spread to lymph nodes or other organs.
- MRI: For patients who cannot receive CT contrast, or for evaluating venous tumor thrombus and brain metastases.
- Renal Ultrasound: First-line screening tool, especially for incidental findings.
For small renal masses or when imaging cannot distinguish benign from malignant tumors (e.g., oncocytoma vs. renal cell carcinoma), we perform CT or ultrasound-guided biopsy to confirm histology and subtype (clear cell, papillary, chromophobe, etc.)—guiding treatment decisions without unnecessary surgery.
- Chest CT: Rules out lung metastases (most common site).
- PET-CT: For high-risk or metastatic disease, detects spread to bones, liver, or distant lymph nodes.
- Bone Scan: If bone pain or elevated alkaline phosphatase.
Using NGS (Next-Generation Sequencing), we analyze VHL, PBRM1, BAP1, SETD2, MTOR, MET, PD-L1, MSI/dMMR, NTRK fusions, and over 300 cancer-related genes. This determines whether your tumor will respond to VEGF-targeted TKIs (sunitinib, pazopanib, axitinib), mTOR inhibitors (everolimus), immunotherapy (PD-1/PD-L1 inhibitors), or clinical trials of novel bispecific antibodies—ensuring your treatment is matched to your tumor’s unique biology, not a generic protocol.
